Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency

Trial Profile

Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency

Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Oct 2017

At a glance

  • Drugs SGS 742 (Primary)
  • Indications Inborn error amino acid metabolic disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Oct 2016 Planned primary completion date changed from 1 Nov 2018 to 1 Jun 2018.
    • 08 Jun 2016 Time frame of endpoints changed from 3 years to on-going and phase change from 1/2 to 2 also treatment arms changed from 2 arms to 4 arms.
    • 08 Jun 2016 Planned End Date changed from 1 Nov 2016 to 1 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top